Success Metrics

Active Trials
2(40%)

Phase Distribution

Ph phase_1
2
40%
Ph not_applicable
2
40%
Ph phase_2
1
20%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Other(2)

Detailed Status

Recruiting2
unknown2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 21 (20.0%)
N/A2 (40.0%)

Trials by Status

not_yet_recruiting120%
recruiting240%
unknown240%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_1

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

NCT06287944
not_yet_recruitingphase_2

Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

NCT07582172
recruitingphase_1

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

NCT06195891
unknownnot_applicable

Total Marrow and Lymphoid Irradiation and Chemotherapy for High-Risk Acute Leukemia

NCT03408223
unknownnot_applicable

Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia

NCT03408210

Clinical Trials (5)

Showing 5 of 5 trials
NCT06287944Phase 1

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Recruiting
NCT07582172Phase 2

Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Not Yet Recruiting
NCT06195891Phase 1

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

Recruiting
NCT03408223Not Applicable

Total Marrow and Lymphoid Irradiation and Chemotherapy for High-Risk Acute Leukemia

Unknown
NCT03408210Not Applicable

Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia

Unknown

All 5 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
5